Maze Therapeutics Announces Appointment Of Experienced Biotech Executive Hervé Hoppenot As Chairman Of Its Board Of Directors

Maze Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for patients with kidney and metabolic diseases, has announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors. He succeeds Charles Homcy, M.D., who will continue to serve as a member of the Board. Hervé Hoppenot brings more than thirty years of leadership experience in therapeutic development and commercial strategy to Maze’s Board. His extensive background in the pharmaceutical and biotechnology industries positions him well to support the company’s continued growth and clinical progress.

Before joining Maze Therapeutics, Mr. Hoppenot served as Chief Executive Officer of Incyte Corporation from 2014 to 2025 and as Chairman from 2015 to 2025. Under his leadership, Incyte grew into a leading biopharmaceutical company known for its innovation in oncology and inflammation. Prior to his time at Incyte, he held several key roles at Novartis, including President of Novartis Oncology, Chief Commercial Officer, and Head of Global Product Strategy & Scientific Development. Earlier in his career, he worked at Aventis (formerly Rhône-Poulenc), where he served as Vice President of U.S. Oncology.

Mr. Hoppenot stated, “I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics. With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of MZE829 targeting APOL1-mediated kidney disease, Maze is well-positioned to deliver meaningful progress. The team has consistently demonstrated strong execution, and I look forward to working with them to advance therapies that can transform the lives of patients with kidney and metabolic diseases.”

Jason Coloma, Ph.D., chief executive officer of Maze, said in a statement, “Hervé is a proven company builder, having transformed Incyte from a single-product company into a diversified biotech leader and driving its growth from $350 million to more than $4 billion in revenue as CEO. We are honored to welcome him as Chairman as we accelerate Maze’s progress toward several key milestones in 2026, including initiating Phase 2 trials in PKU and CKD for MZE782 and an initial topline Phase 2 data readout for MZE829 in APOL1-mediated kidney disease. 

He also added, “Hervé’s leadership will be invaluable as we advance transformative therapies for patients with kidney and metabolic diseases. We are also deeply grateful to Charles, a Maze co-founder, for his outstanding service as Chairman. His guidance has been instrumental in shaping our scientific foundation and clinical progress, and we are delighted he will continue to contribute as a member of our Board and R&D Committee.”

In addition to his new role at Maze Therapeutics, Mr. Hoppenot currently serves on the boards of Incyte, Laboratoires Pierre Fabre, N-Power Medicine, and Bicycle Therapeutics. He holds a degree from ESSEC Business School in France. This leadership transition marks an important step for Maze Therapeutics as it continues advancing its precision medicine pipeline to address significant unmet needs in kidney and metabolic diseases.